Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating Tumor DNA Harboring the BRAFV600E Mutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients.

Thyroid : official journal of the American Thyroid Association - 1 Dec 2021

Sato Ayaka, Tanabe Masahiko, Tsuboi Yumi, Niwa Takayoshi, Shinozaki-Ushiku Aya, Seto Yasuyuki, Murakami Yoshinori

Abstract excerpt

Background: The significance of circulating tumor DNA (ctDNA) in primary papillary thyroid cancer (PTC) is yet to be well established. This study aimed to clarify whether ctDNA carrying the BRAFV600E mutation in plasma from primary PTC patients before and after surgery can predict outcomes. Methods: Twenty-two primary PTC patients without distant metastasis, who underwent surgical resection at the University of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Lymphatic Metastasis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Neoplasms

Share to Thyroidectomy

Source

Identifiers

PMID: 34541884
DOI: 10.1089/thy.2021.0267

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating Tumor DNA Harboring the BRAFV600E Mutation May Predict Poor Outcomes of Primary Papillary Thyroid Cancer Patients.PMID 34541884Read ↗

Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.Semantic proximity Read ↗

Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis.Semantic proximity Read ↗

Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma.Semantic proximity Read ↗

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.Semantic proximity Read ↗

Can mutation abundance assess the biological behavior of BRAFV600E-positive papillary thyroid carcinoma?Semantic proximity Read ↗

The ratio of BRAFV600E alleles can be used to assess the biological behavior of papillary thyroid carcinomaSemantic proximity Read ↗

BRAFV600E mutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer.Semantic proximity Read ↗

Prediction of the Aggressive Clinical Course of Papillary Thyroid Carcinoma Based on Fine Needle Aspiration Biopsy Molecular Testing.Semantic proximity Read ↗

Detection of BRAF Mutation on Fine Needle Aspiration Biopsy Specimens: A New Diagnostic Tool for Papillary Thyroid CancerSemantic proximity Read ↗

High Concordance in Molecular Profiles Between Primary Tumors and Matched Lymph Node Metastases in Differentiated Thyroid Carcinoma: Implications for Clinical Sample SelectionSemantic proximity Read ↗

Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review.Semantic proximity Read ↗

Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.